AngioDynamics Q1 sales rally 6.9% to $80.9 million
Compartilhar
AngioDynamics (NASDAQ:ANGO) reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9% from the prior-year period.
AngioDynamics (NASDAQ:ANGO) reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9% from the prior-year period.
AngioDynamics (NASDAQ:ANGO) reported its financial results for the third quarter of fiscal year 2026, ended February 28, 2026, on Thursday, April 2.
AngioDynamics (NASDAQ:ANGO) announced that the U.S. Food and Drug Administration approved its Investigational Device Exemption application to begin the RELIEF feasibility study.
AngioDynamics (NASDAQ:ANGO) on Tuesday reported fiscal second-quarter results that highlighted continued momentum in its high-margin Med Tech portfolio, with overall net sales rising 8.8% year over year to $79.4 million for the period ended Nov. 30, 2025.
AngioDynamics (NASDAQ:ANGO) reported fiscal fourth-quarter revenue of $86.6 million, up 8%, as Med Tech growth offset a wider $11.4 million GAAP net loss.
